GN
GNPX.US Genprex Inc
- Market cap
- USD 1.70M
- P/E
- -
- P/B
- 0.12x
- ROE
- -127.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GNPX.US undervalued?
Graham numberThe Graham number of Genprex Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genprex Inc fundamental analysis
No fundamental analysis for Genprex Inc yet.
Genprex Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genprex Inc
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead pro…
Full company profileGenprex Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genprex Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 0.00 | 0.00 | 0.00 | -13.1K | -22.8K | -22.5K | -25.6K | -15.0K | -6.69K | - | - |
| Operating Income | -4.13M | -3.31M | -12.4M | -10.7M | -18.0M | -20.7M | -23.8M | -31.1M | -21.2M | -15.5M | - |
| EBITDA | -4.13M | -3.31M | -12.3M | -10.6M | -17.9M | -20.6M | -23.7M | -30.8M | -21.1M | -15.5M | - |
| Net Income | -4.13M | -3.31M | -12.4M | -10.7M | -17.9M | -20.7M | -23.7M | -30.9M | -21.1M | -16.2M | -17.5M |
| EPS | -16,797 | -12,698 | -0.90 | -29,271 | -22,234 | -19,313 | -21,780 | -24,827 | -5,797 | -383 | -22 |
| Balance Sheet | |||||||||||
| Total Assets | 1.91M | 1.26M | 9.27M | 3.53M | 31.4M | 42.9M | 25.1M | 10.7M | 4.12M | 10.2M | 17.5M |
| Total Liabilities | 286K | 831K | 388K | 511K | 451K | 1.59M | 2.81M | 3.25M | 2.50M | 2.20M | 3.80M |
| Shareholders' Equity | 1.62M | 429K | 8.88M | 3.02M | 30.9M | 41.3M | 22.3M | 7.42M | 1.62M | 7.96M | 13.7M |
| Cash & Short-term Investments | 1.60M | 161K | 8.60M | 2.00M | 27.3M | 38.6M | 21.0M | 6.74M | 1.60M | 7.83M | 15.3M |
| Total Debt | - | 202K | 92.8K | 92.8K | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.25M | -2.17M | -6.85M | -6.92M | -13.9M | -14.3M | -17.8M | -24.7M | -17.1M | -15.3M | -14.9M |
| Capital Expenditure | 89.5K | 63.4K | 103K | 947K | 2.34M | 83.8K | 4.00 | 71.4K | 0.00 | 1.00 | 8.00 |
| Free Cash Flow | -1.34M | -2.24M | -6.95M | -7.87M | -16.3M | -14.4M | -17.8M | -24.8M | -17.1M | -15.3M | -14.9M |
| Ratios | |||||||||||
| ROE | -254.3% | -773.3% | -139.3% | -352.4% | -58.0% | -50.1% | -106.6% | -416.1% | -1,303.0% | -203.8% | -127.7% |
| ROA | -216.3% | -263.1% | -133.5% | -301.5% | -57.2% | -48.2% | -94.6% | -289.2% | -511.9% | -159.7% | -100.0% |
| Debt to Equity | - | 0.47x | 0.01x | 0.03x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genprex Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 277M | 76,090 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:22 on Jul 16, 2026.
Who owns Genprex Inc
- Insiders 0.22%
- Institutions 1.30%
- Public & others 98.48%
- Shares outstanding 820K
- Free float 819K
Top funds holding GNPX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 9.12K | 1.11% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 70.00 | 0.01% | 0.00% | Sep 2026 |
| EC SICAV EverCapital Invms UCITS I Ins I | 2.00 | 0.00% | +100.00% | Sep 2026 |
Top institutions holding GNPX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Fiduciary Trust Co | 78.1K | 0.43% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 72.1K | 0.40% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 60.3K | 0.33% | +80.83% | Jun 2026 |
| Vanguard Capital Management, LLC | 36.4K | 0.20% | +510.92% | Jun 2026 |
| Mayflower Financial Advisors, LLC | 20.0K | 0.11% | 0.00% | Jun 2026 |
| UBS Group AG | 4.49K | 0.02% | +448,800.00% | Jun 2026 |
| Cheviot Value Management, Inc. | 1.00K | 0.01% | 0.00% | Jun 2026 |
| BlackRock Inc | 188.00 | 0.00% | 0.00% | Jun 2026 |
| HARBOUR INVESTMENTS, INC. | 108.00 | 0.00% | -10.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 82.00 | 0.00% | -64.66% | Jun 2026 |
| SBI Securities Co Ltd | 48.00 | 0.00% | 0.00% | Jun 2026 |
| Hanson Mcclain Inc | 23.00 | 0.00% | +666.67% | Jun 2026 |
| Integrated Wealth Concepts LLC | 21.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Global Retirement Partners, LLC. | 2.00 | 0.00% | +100.00% | Jun 2026 |
| Danske Bank A/S. | 2.00 | 0.00% | +100.00% | Jun 2026 |
| Bogart Wealth, LLC | 2.00 | 0.00% | +100.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 2.00 | 0.00% | +100.00% | Jun 2026 |
| JPMorgan Chase & Co | 2.00 | 0.00% | 0.00% | Jun 2026 |
Genprex Inc company profile
- Company name
- Genprex Inc
- Ticker
- GNPX.US
- Exchange
- USA Stocks
- Listed since
- Mar 29, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- 3300 Bee Cave Road, Austin, TX, United States, 78746
- Phone
- 877 774 4679
- Website
- genprex.com
About Genprex Inc
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. It also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistant NSCLC, other tumor suppressor genes, and Glioblastoma, which is in preclinical studies. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive; New York University; UTHealth Houston; and University of Pittsburgh. The company also has a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that for the prediction of patient response to Reqorsa Gene Therapy. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.
Genprex Inc management
7- Mr. Ryan M. Confer M.S.President, CEO, CFO & Director · born 1982
- Dr. Mark S. Berger M.D.Chief Medical Officer · born 1955
- Mr. David M. SchlossSenior Vice President of Human Resources
- Mr. Thomas C. Gallagher Esq.Senior Vice President of Intellectual Property & Licensing
- Dr. Suzanne Thornton-Jones Ph.D.Senior Vice President of Regulatory Affairs & Quality
- Ms. Celina LaneyChief of Staff
- Mr. Greg Jancarik C.M.A., CPA, M.B.A.Senior Director & Corporate Controller